Seroprevalence of anti-SARS-CoV-2 spike protein antibodies in the New York Metropolitan Area
As of July 2nd 2020, 51,629 individuals were screened by the Mount Sinai Health System to recruit volunteers for convalescent plasma therapy. The individuals screened either had confirmed SARS-CoV-2 infections by PCR, or suspected disease, defined as a physician attributing suspected symptoms to SARS-CoV-2 or exposure to someone infected with SARS-CoV-2.
In order to determine the parameters of a viable candidate for volunteering, an enzyme-linked immunosorbent assay (ELISA) was administered to the participants. Those with titers greater than or equal to 1:80 were considered to have undergone seroconversion.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium
Introduction for Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Summary for Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
Antibody Testing in Germany
Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients
SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan–implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2
Diagnostic Tool for Coronavirus Being Developed by University of Warwick
Saliva could be an alternative fluid to test COVID-19 antibodies
Seroprevalence of anti-SARS-CoV-2 spike protein antibodies in the New York Metropolitan Area